The proposed changes are relatively modest, yet they represent an important procedural step forward in the implementation of ...

As the Trump administration begins to make its mark on the Medicare drug price negotiation program and pursue its own policies on prescription drugs, litigation over program continues. In the two ...

An appeals court has ruled against a legal challenge to the Drug Price Negotiation Program. On Wednesday, the U.S. Court of Appeals for the Sixth Circuit sided with the Department of Health and Human ...

As President Donald Trump touts new deals to cut the cost of blockbuster drugs like Wegovy and Zepbound, he’s barely mentioned Medicare’s drug price negotiation program — even though the government is ...

The One Big Beautiful Bill Act removed a number of orphan drugs from being subject to price negotiations, and this could cost the Medicare program $8.8 billion over the course of about 10 years. That ...

On Tuesday, the Centers for Medicare & Medicaid Services (CMS) announced the next 15 drugs that will be subject to government price negotiations. This is the third round of selections, bringing the ...

On Monday, the Supreme Court declined to hear appeals from pharmaceutical companies opposing the federal government's ability to negotiate drug prices under Medicare. This decision maintains the lower ...

“If the Companies dislike the prices the government is willing to pay, they are free to stop doing business with the government.” – Third Circuit majority The U.S. Court of Appeals for the Third ...

“The Program cannot qualify as a physical taking under the Takings Clause because it does not ‘compel the surrender’ of property, or impose any ‘physical invasion or restraint upon’ it, and the owner ...

On May 12, 2025, the Centers for Medicare & Medicaid Services (CMS) issued draft guidance for the third cycle of the IRA’s Medicare Drug Price Negotiation Program (Negotiation Program). This draft ...